Heidelberg ImmunoTherapeutics is a clinical stage biopharmaceutical company focusing on the clinical development of innovative immunotherapeutics for the treatment of viral diseases and cancer.
The company’s lead product, HDIT101, is being developed for the treatment of herpes simplex virus (HSV) infections, which are affecting several million people worldwide. Oral and genital herpes are the most common conditions. A particular challenge is the treatment of herpes simplex viruses resistant to common antivirals. HDIT101 may offer a new, efficacious treatment option in these cases. Information about ongoing and future clinical studies can be found here.